AzTrials
AzTrials

Trained AthletesTULiPNCT07897357

Trained vs. Untrained: Lower Extremity Pressure Changes

A study testing Lower body positive and negative pressure in people with Trained Athletes and Untrained, run by University of Alberta at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Research shows that how well oxygen moves from the lungs into the blood (called lung diffusing capacity) is linked to a person's aerobic fitness and endurance training. People who exercise regularly often have different lung and heart responses than people who do not. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Trained Athletes, Untrained
What is being tested?
Lower body positive and negative pressure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteCanada
Study dates
9 Oct 2026to 1 Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • 18-40 years old.

Who cannot join

  • Severe obesity (body mass index >35 kg/m2).
  • Self-reported blood donation or transfusion in the past 60 days. Large artificial fluctuations in blood volume may impact the findings of the present study.
  • Pregnancy. To confirm this, women not using contraception will be given a pregnancy test. Pregnancy presents additional complications and may confound the results of the study; therefore, pregnant women will be excluded.
  • Known chronic disease (heart failure, hypertension, diabetes, asthma, chronic obstructive pulmonary disease, renal disease).
  • Participants with known postural orthostatic tachycardic syndrome or orthostatic hypotension.
  • Participants who currently smoke cigarettes (within the last month) or those who have >1 pack-year smoking history.
  • Participants who currently smoke cannabis products (within the last month) or those who have >1 joint-year cannabis history.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Desi P Fuhr, MSc contact

780-492-1121

fuhr@ualberta.ca

Canada1 site, 1 recruiting
  • Clinical Physiology Laboratory

    Edmonton, Alberta, T6G 2R3

    Desi P Fuhr, MSc, 780-492-1121, fuhr@ualberta.ca

    Michael K Stickland, PhD, 780-492-3995, michael.stickland@ualberta.ca

    Recruiting

Other trials in Canada

About this study

Official title: Central Blood Volume Shifts in Healthy Adults With Varying Levels of Fitness: Effects on Lung Diffusing Capacity

Research shows that how well oxygen moves from the lungs into the blood (called lung diffusing capacity) is linked to a person's aerobic fitness and endurance training. People who exercise regularly often have different lung and heart responses than people who do not. The exact reasons for these differences are still unclear. This study will test one possible explanation: highly trained people may handle changes in the amount of blood returning to the heart differently than people who are not trained. We want to learn how the blood vessels in the lungs react when the amount of blood entering the heart changes, and how this reaction is affected by fitness level. To do this, we will change how much blood returns to the heart by applying air pressure around the legs, similar to a light vacuum. These changes are expected to be similar to what happens when someone moves from lying down to standing up.

Read the detailed description

Purpose and hypothesis

The purpose of the current study is to determine the impact of endurance training status and biological sex on pulmonary diffusing capacity for carbon monoxide (DLCO) and its components (pulmonary capillary blood volume [Vc] and pulmonary membrane diffusing capacity [Dm]) during acute changes in central blood volume using varying levels of lower body positive and negative pressure (LBPP and LBNP) and head down and head up tilt (HDT and HUT).

The investigators hypothesize that for a given reduction (i.e., LBNP, HUT) or increase (i.e., LBPP, HDT) in central blood volume, endurance-trained individuals will demonstrate greater changes in DLCO compared to untrained individuals. As a second exploratory aim, the investigators hypothesize that females will have larger changes in DLCO compared to males.

Research Method/Procedures

All visits will happen on separate days with at least 24 hours between visits. All visits will take place within 4 months.

Visit 1: Screening

On the screening day, the participant will complete the informed consent procedure, fill out a medical history form, and be screened for exercise using the modified medical research council (mMRC) dyspnea scale, PAR-Q+ exercise readiness questionnaire and the Physical Activity and Sedentary Behaviour Questionnaire (PASB-Q). The investigators will then perform pulmonary function tests on each participant. Finally, the participant will complete a graded exercise test on an upright cycle ergometer to volitional exhaustion to determine maximal oxygen consumption (V̇O2max). Evaluation of dyspnea including intensity and unpleasantness will be performed at each workload. Further, reasons for test termination, dyspnea, and qualitative descriptors of dyspnea will be evaluated at peak exercise. Hemoglobin concentration will be measured via finger prick prior to and following completion of exercise testing.

Visit 2: Central Blood Volume Manipulation and DLCO

The participant will perform the DLCO test at various levels of LBNP/LBPP ranging from -80 mmHg to +40 mmHg, or HUT/HDT ranging between 90° and -12°. Head tilt and lower body pressure changes provide a similar intervention that can be used interchangeably based on equipment availability. Changes in central blood volume during LBNP/HUT are equivalent to standing upright (-80 mmHg LBNP or 90° HUT), and changes in central blood volume during LBPP/HDT are equivalent to someone lying down with their feet above their head (+40 mmHg LBPP or -12° HDT). For the LBNP/LBPP trials, participants will lay supine with their lower body (from the iliac crest to their toes) inside the pressure chamber. The participant's lower body will be sealed within the differential pressure chamber using a neoprene skirt to prevent any air leakage from the insides of the chamber. Negative and positive pressures are induced by a vacuum pump that either reduces or increases pressure inside the chamber in a controlled and precise manner. The vacuum pump is controlled by a trained member of the research team, and chamber pressure is continuously monitored via a digital manometer. For the HUT/HDT trials, the participant will lie supine on a tilt table. The table will be electronically adjusted to the desired angle at a rate of 1°/second.

Once participants are secured in the lower body pressure chamber or on the tilt table, a certified technician will insert an intravenous (IV) catheter into an antecubital vein which will allow peripheral venous pressure measurements. Participants will also be equipped with a continuous blood pressure monitor, a brachial blood pressure cuff, an electrocardiogram, and a thoracic impedance device. Each stage of LBPP/LBNP or HUT/HDT will begin with two minutes of stabilization followed by two DLCO breath-hold maneuvers. At each stage participants will also breathe on a mouthpiece for two minutes to collect metabolic data: ventilation (V̇E), oxygen consumption (V̇O2), and carbon dioxide production (V̇CO2). Cardiovascular parameters (blood pressure, peripheral venous pressure, heart rate, thoracic impedance) will be measured continuously. Hemoglobin will be measured at each stage via a small (< 1 mL) blood sample from the IV. At the end of the trial, a certified technician will obtain a ~5 mL blood sample from the IV for sex hormone analyses.

Participants will not complete more than 15 DLCO breath holds during each experimental visit. As per recommendations, participants will perform standard DLCO breath-hold maneuvers for 6 seconds, and maneuvers will be performed twice at each stage. A washout period of at least 4 minutes between each breath hold will be completed to ensure adequate recovery and blood gas equilibration.

Visit 3: DLCO with Exercise

Exercise will be used as a physiological stressor to increase central blood volume beyond that of LBPP or HDT. The participant will perform the DLCO maneuvers during exercise at varying exercise intensities (~20%-100% of an individual's V̇O2max). Participants will not complete more than 15 breath holds during the experimental visit. As per recommendations, participants will perform standard DLCO breath-hold maneuvers for 6 seconds, and maneuvers will be performed twice at each stage. At each exercise intensity, participants will breathe on a mouthpiece for two minutes to collect metabolic data; heart rate and peripheral oxygen saturation will be measured continuously for the same two minutes at each intensity. Blood pressure will be measured once per stage with an automatic sphygmomanometer. Hemoglobin via finger prick will also be measured at each intensity. A washout period of at least 2 minutes between each breath hold during exercise will be completed to ensure adequate recovery and blood gas equilibration. At the end of the trial, a certified technician will obtain a ~5 mL blood sample from an antecubital vein for sex hormone analyses.

Visit 4: Ultrasound with LBNP/HUT, LBPP/ HDT, and Exercise

Participants will complete the same interventions as visit 2 (LBNP/LBPP -80 to +40 mmHg, or HUT/HDT 90° to -12°) and visit 3 (exercise at ~20%-100% of an individual's V̇O2max). At each stage of LBNP/LBPP or HUT/HDT, and exercise, a trained sonographer will obtain images of the heart via echocardiography. Participants will then undergo a carbon monoxide rebreathe protocol to estimate blood volume. A certified technician will insert an IV catheter into an antecubital vein to collect serial blood samples. While lying supine, participants will inhale a bolus of carbon monoxide (0.7-1.0 mL/kg bodyweight) mixed with 100% oxygen on a rebreathing circuit for two minutes and will then continue to rest for eight additional minutes. Venous blood samples measuring carboxyhemoglobin before the rebreathe and eight minutes after the rebreathe will allow the calculation of blood volume.

Visit 5: Computed Tomography

Participants will report to a Medical Imaging Centre for the computed tomography (CT) scan. Following a briefing by the Medical Imaging Centre staff, participants will lay supine on the CT scanner and the region of interest in the chest will be obtained. The participant will remain as still as possible and inhale to total lung capacity and hold their breath. During the breath hold, images will be acquired. The participant will then empty their lungs as far as they can and imaging will be repeated.

CT can noninvasively detect features of pulmonary vascular dysfunction. CT outcomes-such as pulmonary artery diameter, vessel pruning, perfusion heterogeneity, and right ventricular morphology-correlate with hemodynamic abnormalities and impaired pulmonary vascular reserve. These imaging biomarkers enable early identification and monitoring of pulmonary vascular disease, providing clinically relevant information beyond conventional structural assessment. In healthy individuals, CT can provide valuable information characterizing pulmonary structure not available using other non-invasive techniques. For example, CT can provide quantitative information on pulmonary vascular and airway branching to show potential structural differences inherent to highly fit individuals. CT is therefore a tool to characterize differences in lung structure which may also potentially explain differences in lung function elucidated by the other measures in this study.

Being tested
Lower body positive and negative pressure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lower body positive and negative pressureOther

    Graded lower body positive pressure (+10, +20, +30 mmHg) and negative pressure (-15, -30, -45, -60 mmHg).

Study groups in NCT07897357
Study groupRoleWhat they receive
All participantsExperimentalAll participants complete all five visits as outlined in the study description.
Receives: Other: Lower body positive and negative pressure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in diffusing capacity for carbon monoxide (DLCO)

    Diffusing capacity of carbon monoxide (DLCO) in selected exercise intensities, lower-body pressures, and body positions. DLCO is measured using the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.

    Measured: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.

  2. Change in capillary blood volume (Vc)

    Capillary blood volume is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.

    Measured: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.

  3. Change in membrane diffusing capacity (Dm)

    Membrane diffusing capacity is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.

    Measured: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Oct 2026
  2. Study start9 Oct 2026 (estimated)
  3. Primary completion15 Dec 2027 (estimated)
  4. Study completion1 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07897357
Sponsor's protocol ID
Pro00160257
Acronym
TULiP
Status last verified
Oct 2026
First submitted
6 Oct 2026
Last updated
27 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Brotto AR, de Waal S, D'Souza AW, Beaudry RI, Ehnes CM, Collins SE, Fuhr DP, van Diepen S, Stickland MK. Impact of body posture on pulmonary diffusing capacity at rest and during exercise in endurance-trained and untrained individuals. J Appl Physiol (1985). 2025 Jan 1;138(1):301-310. doi: 10.1152/japplphysiol.00447.2024. Epub 2024 Dec 16.

    PubMed 39681333
  • Tedjasaputra V, Bouwsema MM, Stickland MK. Effect of aerobic fitness on capillary blood volume and diffusing membrane capacity responses to exercise. J Physiol. 2016 Aug 1;594(15):4359-70. doi: 10.1113/JP272037. Epub 2016 May 12.

    PubMed 26959808
  • Shi X, Crandall CG, Raven PB. Hemodynamic responses to graded lower body positive pressure. Am J Physiol. 1993 Jul;265(1 Pt 2):H69-73. doi: 10.1152/ajpheart.1993.265.1.H69.

    PubMed 8342666
  • Lalande S, Yerly P, Faoro V, Naeije R. Pulmonary vascular distensibility predicts aerobic capacity in healthy individuals. J Physiol. 2012 Sep 1;590(17):4279-88. doi: 10.1113/jphysiol.2012.234310. Epub 2012 Jun 25.

    PubMed 22733662

Questions about this trial

What is this clinical trial studying?

A study testing Lower body positive and negative pressure in people with Trained Athletes and Untrained, run by University of Alberta at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Desi P Fuhr, MSc (780-492-1121, fuhr@ualberta.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in diffusing capacity for carbon monoxide (DLCO) (time frame: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07897357, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in